CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	9 Months Ended		301 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012
Cash Flows from Operating Activities
Net loss	$ (10,123)	$ (9,759)	$ (201,858)
Gain on disposal of discontinued operations			(939)
Gain on disposal of fixed assets			(102)
Adjustments to reconcile net loss to net cash used in operating activities:
Noncash financing costs			316
Noncash inventory impairment			4,417
Noncash patent impairment			2,614
Noncash other income			(709)
Noncash decrease in accounts payable			(1,308)
Depreciation and amortization	106	84	4,262
Noncash stock-based compensation	1,902	1,654	11,435
Common stock issued for agreement not to compete			200
Series B Preferred Stock issued for consulting services			18
Changes in operating assets and liabilities (net effects of purchase of businesses in 1988 and 1994):
Increase in receivables			(199)
Increase in inventory			(4,447)
(Increase) decrease in prepaid expenses and other current assets	(352)	140	(148)
Increase (decrease) in accounts payable and accrued expenses	367	744	9,937
Net cash used in operating activities	(8,100)	(7,137)	(176,511)
Cash Flows from Investing Activities
Change in trading marketable securities			(191)
Capital expenditures	(54)	(15)	(2,447)
Capitalization of patents and patent applications	(578)	(247)	(5,534)
Proceeds from sale of PP&E			225
Cash acquired in purchase of FTI			3
Proceeds from sale of subsidiary, less $12,345 for operating losses during 1990 phase-out period			138
Proceeds from sale of the assets of FTI			2,250
Increase in net assets held for disposal			(213)
Net cash used in investing activities	(632)	(262)	(5,769)
Cash Flows from Financing Activities
Proceeds from issuance of common stock, net of offering costs	33,328	11,509	207,431
Exercise of stock options & warrants	422	3	797
Proceeds from a shareholder transaction			327
Proceeds from issuance of preferred stock			23,688
Purchase of treasury stock			(21,487)
Proceeds from issuance of notes payable			2,839
Principal payments on notes payable			(1,732)
Net cash provided by financing activities	33,750	11,512	211,863
Net increase (decrease) in cash and cash equivalents	25,018	4,113	29,583
Cash and cash equivalents at beginning of period	4,565	2,957
Cash and cash equivalents at end of period	$ 29,583	$ 7,070	$ 29,583